Work

713TiP A phase I study of PRT3789, a potent and selective degrader of SMARCA2 in patients with advanced or metastatic solid tumors and a SMARCA4 mutation

Year: 2023

Type: article

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2023.09.1899

Authors: I. Dagogo-Jack, A. Dowlati, R. Guo, M.M. Awad, A. Swalduz, E. Calvo, V. Moreno Garcia, A.A. Adjei, P. Lorusso, S. Punekar, T.A. Leal, T.A. Yap, A. Italiano, W. Novotny, C. Tankersley, S. Rowe, G. Paris, W. Sun, A.I. Spira, B. Besse

Institutions: Massachusetts General Hospital, University Hospitals Seidman Cancer Center, Case Western Reserve University, Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, Centre Léon Bérard, Hospital Universitario Fundación Jiménez Díaz, Cleveland Clinic, Yale Cancer Center, Yale University, NYU Langone Health, New York University, Winship Cancer Institute, The University of Texas MD Anderson Cancer Center, Université de Bordeaux, Institut Bergonié, Prelude Therapeutics Incorporated (United States), Institut Gustave Roussy, Fondation Gustave Roussy

Language: English

Topic: Chromatin Remodeling and Cancer

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W4387811462

FWCI: 0.224

Cites:

Cited by: 3

Related to: 10